Published in Sci Rep on January 19, 2017
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev (2006) 15.09
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol (2008) 8.51
Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat Biotechnol (2002) 6.68
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res (2010) 4.70
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today (2006) 4.24
Quantification of short term signaling by the epidermal growth factor receptor. J Biol Chem (1999) 4.19
Prediction and validation of the distinct dynamics of transient and sustained ERK activation. Nat Cell Biol (2005) 4.13
Multicomponent therapeutics for networked systems. Nat Rev Drug Discov (2005) 3.99
A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov (2007) 3.22
Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov (2009) 3.20
The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci (2005) 3.02
A mathematical model of caspase function in apoptosis. Nat Biotechnol (2000) 2.85
Chemical combination effects predict connectivity in biological systems. Mol Syst Biol (2007) 2.42
Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol Cancer Ther (2010) 2.38
Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell (1996) 2.31
Mathematical modeling identifies inhibitors of apoptosis as mediators of positive feedback and bistability. PLoS Comput Biol (2006) 2.30
Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov (2006) 2.23
Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals. Mol Cell (2012) 2.11
Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol (1999) 2.00
Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem (2006) 1.83
Control of MAPK signalling: from complexity to what really matters. Oncogene (2005) 1.82
Stimulus design for model selection and validation in cell signaling. PLoS Comput Biol (2008) 1.75
Scaffolding protein Grb2-associated binder 1 sustains epidermal growth factor-induced mitogenic and survival signaling by multiple positive feedback loops. J Biol Chem (2006) 1.75
Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res (2011) 1.73
Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab (2007) 1.66
Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Discov (2007) 1.60
Protein-protein interaction map inference using interacting domain profile pairs. Bioinformatics (2001) 1.52
Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells. Elife (2015) 1.46
The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J Biol Chem (2005) 1.43
Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer (2006) 1.40
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol (2006) 1.37
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol Cancer Ther (2009) 1.32
Prediction of drug combination chemosensitivity in human bladder cancer. Mol Cancer Ther (2007) 1.29
Interaction of Rac1 with GTPase-activating proteins and putative effectors. A comparison with Cdc42 and RhoA. J Biol Chem (1998) 1.21
Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin Cancer Res (2011) 1.17
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clin Cancer Res (2010) 1.15
A domain-based approach to predict protein-protein interactions. BMC Bioinformatics (2007) 1.14
The role of transient ERK2 signals in fibronectin- and insulin-mediated DNA synthesis. J Cell Sci (2000) 1.12
Chemogenomic profiling predicts antifungal synergies. Mol Syst Biol (2009) 1.11
Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets. Sci Signal (2013) 1.08
Network quantification of EGFR signaling unveils potential for targeted combination therapy. Mol Syst Biol (2013) 1.07
The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. Exp Hematol (2006) 1.03
Methods for optimizing antiviral combination therapies. Bioinformatics (2003) 1.02
Model analysis of difference between EGF pathway and FGF pathway. Biochem Biophys Res Commun (2004) 1.02
CDA: combinatorial drug discovery using transcriptional response modules. PLoS One (2012) 1.01
DNA damage by anti-cancer agents resolved at the nucleotide level of a single copy gene: evidence for a novel binding site for cisplatin in cells. Nucleic Acids Res (1994) 1.01
Drug inhibition profile prediction for NFκB pathway in multiple myeloma. PLoS One (2011) 1.01
The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells. Leukemia (2011) 1.01
Perturbation biology: inferring signaling networks in cellular systems. PLoS Comput Biol (2013) 1.00
A formal model for analyzing drug combination effects and its application in TNF-alpha-induced NFkappaB pathway. BMC Syst Biol (2010) 0.99
Systematic quantitative characterization of cellular responses induced by multiple signals. BMC Syst Biol (2011) 0.99
Efficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing. Nat Chem Biol (2011) 0.97
Cytokine combination therapy prediction for bone remodeling in tissue engineering based on the intracellular signaling pathway. Biomaterials (2012) 0.95
MAPK cascade possesses decoupled controllability of signal amplification and duration. Biophys J (2004) 0.94
The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. J Invest Dermatol (2010) 0.94
A new validated mathematical model of the Wnt signalling pathway predicts effective combinational therapy by sFRP and Dkk. Biochem J (2012) 0.92
The response of cancers to BRAF inhibition underscores the importance of cancer systems biology. Sci Signal (2012) 0.87
Computational analysis of the roles of ER-Golgi network in the cell cycle. BMC Syst Biol (2014) 0.87
5-Aza-2'-deoxycytidine and depsipeptide synergistically induce expression of BIK (BCL2-interacting killer). Biochem Biophys Res Commun (2006) 0.86
Chemogenomics and orthology-based design of antibiotic combination therapies. Mol Syst Biol (2016) 0.85
Prediction of in vivo synergistic activity of antiangiogenic compounds by gene expression profiling. Cancer Res (2002) 0.85
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. J Neurooncol (2011) 0.85
Predicting and characterizing selective multiple drug treatments for metabolic diseases and cancer. BMC Syst Biol (2012) 0.81
Synergistic activation of signalling to extracellular signal-regulated kinases 1 and 2 by epidermal growth factor and 4 beta-phorbol 12-myristate 13-acetate. Eur J Biochem (2004) 0.79
A computer simulation approach to assessing therapeutic intervention points for the prevention of cytokine-induced cartilage breakdown. Arthritis Rheumatol (2014) 0.79
QSSPN: dynamic simulation of molecular interaction networks describing gene regulation, signalling and whole-cell metabolism in human cells. Bioinformatics (2013) 0.79
Simulating EGFR-ERK signaling control by scaffold proteins KSR and MP1 reveals differential ligand-sensitivity co-regulated by Cbl-CIN85 and endophilin. PLoS One (2011) 0.78
Taxol anticancer activity and DNA binding. Mini Rev Med Chem (2005) 0.78
Influence of kinetics of drug binding on EGFR signaling: a comparative study of three EGFR signaling pathway models. Proteins (2011) 0.77
[Treatment of acute renal insufficiency using prostaglandin E2 in surgical patients]. Klin Khir (1990) 0.76
Generation of GABA-synthesizing nerve cells cultured from embryonic cortex cerebri of mice with and without cell-to-cell contacts. Anat Embryol (Berl) (1990) 0.76